Champions Oncology, Inc.

NasdaqCM:CSBR Stock Report

Market Cap: US$70.9m

Champions Oncology Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Champions Oncology.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Life Sciences earnings growth18.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

Analysis Article • Jul 30

Is Champions Oncology (NASDAQ:CSBR) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Sep 16

The Market Lifts Champions Oncology, Inc. (NASDAQ:CSBR) Shares 27% But It Can Do More

Champions Oncology, Inc. ( NASDAQ:CSBR ) shareholders would be excited to see that the share price has had a great...
Analysis Article • Jul 08

Champions Oncology, Inc.'s (NASDAQ:CSBR) Shares Leap 29% Yet They're Still Not Telling The Full Story

Champions Oncology, Inc. ( NASDAQ:CSBR ) shares have had a really impressive month, gaining 29% after a shaky period...
Seeking Alpha • Jun 16

Champions Oncology: Biological IP Is The Real Asset - Not Preclinical Services

Summary Champions Oncology is transitioning from a traditional CRO to also a high-margin data licensing platform, unlocking new revenue and margin potential. The market undervalues CSBR, not reflecting its evolving business model and scalable, defensible oncology data assets in its current valuation. CSBR’s unique, clinically-annotated PDX dataset and early AI/data licensing deals offer significant future upside as the business scales. Given its micro-cap status and early-stage data monetization, I rate CSBR a speculative Buy, best suited for a small portfolio position. Read the full article on Seeking Alpha
Analysis Article • May 20

Positive Sentiment Still Eludes Champions Oncology, Inc. (NASDAQ:CSBR) Following 26% Share Price Slump

To the annoyance of some shareholders, Champions Oncology, Inc. ( NASDAQ:CSBR ) shares are down a considerable 26% in...
Analysis Article • Apr 05

Investors Give Champions Oncology, Inc. (NASDAQ:CSBR) Shares A 28% Hiding

Champions Oncology, Inc. ( NASDAQ:CSBR ) shareholders that were waiting for something to happen have been dealt a blow...
Analysis Article • Feb 04

Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)

Key Insights Champions Oncology's estimated fair value is US$10.10 based on 2 Stage Free Cash Flow to Equity With...
Analysis Article • Dec 10

Sentiment Still Eluding Champions Oncology, Inc. (NASDAQ:CSBR)

Champions Oncology, Inc.'s ( NASDAQ:CSBR ) price-to-sales (or "P/S") ratio of 1.3x might make it look like a strong buy...
Analysis Article • Oct 24

Companies Like Champions Oncology (NASDAQ:CSBR) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jun 14

It's A Story Of Risk Vs Reward With Champions Oncology, Inc. (NASDAQ:CSBR)

With a price-to-sales (or "P/S") ratio of 1.4x Champions Oncology, Inc. ( NASDAQ:CSBR ) may be sending bullish signals...
Analysis Article • Sep 28

Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
Seeking Alpha • Jul 21

Champions Oncology Non-GAAP EPS of -$0.02, revenue of $12.9M

Champions Oncology press release (NASDAQ:CSBR): Q4 Non-GAAP EPS of -$0.02. Revenue of $12.9M (+21.7% Y/Y).
Analysis Article • Oct 14

We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation

The underwhelming share price performance of Champions Oncology, Inc. ( NASDAQ:CSBR ) in the past three years would...
Analysis Article • Jun 21

We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Apr 09

Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?

In this article we are going to estimate the intrinsic value of Champions Oncology, Inc. ( NASDAQ:CSBR ) by taking the...
Analysis Article • Mar 19

Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. Indeed, Champions Oncology...
Analysis Article • Mar 02

The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
Analysis Article • Feb 04

Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?

Champions Oncology, Inc. ( NASDAQ:CSBR ), might not be a large cap stock, but it received a lot of attention from a...
Analysis Article • Jan 14

Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?

The big shareholder groups in Champions Oncology, Inc. ( NASDAQ:CSBR ) have power over the company. Institutions will...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Champions Oncology has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:CSBR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
7/31/202661-1-6-6N/A
4/30/202659-1-5-4N/A
1/31/202658-244N/A
10/31/202558266N/A
7/31/202557378N/A
4/30/202557577N/A
1/31/2025596-1-1N/A
10/31/202454-1-3-3N/A
7/31/202452-3-2-2N/A
4/30/202450-7-7-6N/A
1/31/202449-10-7-5N/A
10/31/202350-10-5-3N/A
7/31/202353-8-30N/A
4/30/202354-514N/A
1/31/202354-335N/A
10/31/202254068N/A
7/31/202252046N/A
4/30/202249146N/A
1/31/202247014N/A
10/31/2021440-40N/A
7/31/2021430-4-1N/A
4/30/2021410-5-2N/A
1/31/202139-1-13N/A
10/31/202037-203N/A
7/31/202035-102N/A
4/30/202032-2N/A3N/A
1/31/2020310N/A1N/A
10/31/201929-1N/A2N/A
7/31/201928-1N/A1N/A
4/30/2019270N/A2N/A
1/31/2019240N/A2N/A
10/31/2018230N/A1N/A
7/31/2018210N/A1N/A
4/30/201820-1N/A-1N/A
1/31/201819-3N/A-1N/A
10/31/201718-5N/A-2N/A
7/31/201717-5N/A-2N/A
4/30/201715-7N/A-3N/A
1/31/201715-7N/A-4N/A
10/31/201614-8N/A-4N/A
7/31/201612-10N/A-6N/A
4/30/201611-10N/A-6N/A
1/31/201612-12N/A-8N/A
10/31/201511-12N/A-10N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if CSBR's forecast earnings growth is above the savings rate (3.7%).

Earnings vs Market: Insufficient data to determine if CSBR's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if CSBR's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if CSBR's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if CSBR's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CSBR's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 18:02
End of Day Share Price 2026/09/11 00:00
Earnings2026/07/31
Annual Earnings2026/04/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Champions Oncology, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Paul KnightBrean Capital Historical (Janney Montgomery)
Matthew HewittCraig-Hallum Capital Group LLC
Scott HenryRoth Capital Partners